Research programme: hepatitis C virus polymerase inhibitors - B&C Pharma/XTL

Drug Profile

Research programme: hepatitis C virus polymerase inhibitors - B&C Pharma/XTL

Alternative Names: BC 2329; HCV-SM

Latest Information Update: 11 Jul 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator B&C Pharma
  • Class Small molecules
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Hepatitis C

Most Recent Events

  • 28 Dec 2005 This programme is still in active development
  • 19 Jan 2004 Data presented at the Frontiers in drug development for Viral Hepatitis - Hep DART 2003 (Hep DART-2003) have been added to the adverse events, pharmacokinetics and pharmacodynamics sections
  • 07 Jul 2003 A potential drug candidate, HepeXTM-C SM1, has been identified for further development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top